Back to Medicines A to Z. Salbutamol is used to relieve symptoms of asthma and chronic obstructive pulmonary disease COPD such as coughing, wheezing and feeling breathless. It works by relaxing the muscles of the airways into the lungs, which makes it easier to breathe. Salbutamol comes in an inhaler puffer. Salbutamol inhalers are usually blue. Salbutamol is sometimes given as tablets, capsules or syrup for people who cannot use an inhaler very well.
It can also be given using a nebuliser, but this is usually only if you have severe asthma or COPD. A nebuliser is a machine that helps you breathe in your medicine as a mist, using a mask or a mouthpiece. You can use a nebuliser in hospital or you may be given one to manage your condition at home. Take our survey. If you have a lactose intolerance, however, the amount of lactose in salbutamol products is too small to cause you any problems. Only use your salbutamol when you need it.
This may be when you notice symptoms, such as coughing, wheezing, shortness of breath and tightness in the chest or you know that you are going to do an activity that can make you breathless, for example climbing stairs or sport. You should feel a difference to your breathing within a few minutes. Salbutamol is sometimes prescribed to prevent breathing symptoms happening in the first place.
This could be before a trigger such as exercise or exposure to pets. In this situation, the normal dose is still 1 or 2 puffs at a time. Make an appointment to see your doctor, pharmacist or nurse if you need to use your inhaler:. In a sudden asthma attack you can use your inhaler more and take up to 10 puffs.
Wait 30 seconds and always shake the inhaler between doses. You can repeat this dose 10 minutes later. For treating severe asthma attacks, salbutamol can be given through a nebuliser. A nebuliser is a machine that delivers the medicine as a mist inhaled through a face mask. This will probably be given to you by your doctor. If you use your inhaler too much, you may notice that your heart beats more quickly than normal and that you feel shaky. These side effects are not dangerous, as long as you do not also have chest pain.
They usually go away within 30 minutes or a few hours at most. Inhalers can be difficult to use and mistakes in the technique can mean very little of the medicine gets into your lungs where you need it. Before using your inhaler, read the manufacturer's printed information leaflet from inside the pack. This leaflet gives you information and diagrams to show you how to use the inhaler, how to keep it clean, and how long to use it before getting a replacement.
It's very important that you use your inhaler properly. This is so you get the right amount of salbutamol into your lungs and the most benefit from it. To get the most from your inhaler, you should have your technique checked regularly. If you're not sure how to use your inhaler, or you have not had your technique checked for a year, ask your doctor, pharmacist or nurse to watch you use it. If you or your child find it difficult to use an inhaler, your doctor may give you a spacer to use with it.
A spacer is a large metal or plastic container with a mouthpiece and a hole for the inhaler. When used with the inhaler it makes it easier to get the right amount of salbutamol into the lungs. Our partner doctors will look after your prescription. All prices on this site are for the entire service. This includes the product, consultation and next day delivery. How many puffs of Ventolin is safe? This content has been written and checked for quality and accuracy by.
Rated 4. Accuhaler mcg. Start Order. Can we help? How We Are Regulated. Payment Options. Next day delivery Prices are inclusive of free consultation. Hydroxyzine: Minor Caution is recommended if hydroxyzine is administered with short-acting beta-agonists due to the potential for additive QT prolongation and risk of torsade de pointes TdP. Postmarketing data indicate that hydroxyzine causes QT prolongation and TdP.
Ibuprofen; Pseudoephedrine: Moderate Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Ibutilide: Minor Ibutilide administration can cause QT prolongation and torsades de pointes TdP ; proarrhythmic events should be anticipated. The potential for proarrhythmic events with ibutilide increases with the coadministration of other drugs that prolong the QT interval. Iloperidone: Minor Iloperidone has been associated with QT prolongation; however, torsade de pointes TdP has not been reported.
According to the manufacturer, since iloperidone may prolong the QT interval, it should be avoided in combination with other agents also known to have this effect. Drugs with a possible risk for QT prolongation that should be avoided with iloperidone include the beta-agonists. Imipramine: Minor Tricyclic antidepressants TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy elevated serum concentrations.
Inotuzumab Ozogamicin: Minor Coadministration of inotuzumab ozogamicin with short-acting beta-agonists may increase the potential for additive QT prolongation and risk of torsade de pointes TdP. Inotuzumab has been associated with QT interval prolongation.
Isocarboxazid: Major Beta-agonists should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors MAOIs due to their sympathomimetic effects. Weigh the risks of coadministration, and where possible, allow a washout period after discontinuation of the MAOI before instituring beta-agonist treatment or vice-versa.
The cardiovascular effects of beta-agonists may be potentiated by concomitant use of MAOIs. Close observation for such effects is prudent, particularly if beta-agonists are administered within 2 weeks of stopping the MAOI.
Monitor blood pressure and heart rate. Isoflurane: Minor Isoflurane, like other halogenated anesthetics, can prolong the QT interval. Isoproterenol: Major Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Itraconazole: Minor Use itraconazole with caution in combination with beta-agonists as concurrent use may increase the risk of QT prolongation. Itraconazole has been associated with prolongation of the QT interval. Ivosidenib: Minor Coadministration of ivosidenib with short-acting beta-agonists may increase the risk of QT prolongation. If concomitant use is necessary, monitor ECGs for QTc prolongation and monitor electrolytes; correct any electrolyte abnormalities as clinically appropriate.
An interruption of therapy and dose reduction of ivosidenib may be necessary if QT prolongation occurs. Prolongation of the QTc interval and ventricular arrhythmias have been reported in patients treated with ivosidenib. Ketoconazole: Minor Coadministration may increase the risk of QT prolongation. Ketoconazole has been associated with prolongation of the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists such as albuterol.
Labetalol: Moderate Use of a betaselective cardioselective beta blocker is recommended whenever possible when this combination of drugs must be used together. Lansoprazole; Amoxicillin; Clarithromycin: Minor The coadministration of beta-agonists with clarithromycin may increase the risk for adverse effects, including prolongation of the QT interval.
Lapatinib: Minor Monitor for evidence of QT prolongation if lapatinib is administered with short-acting beta-agonists. Lapatinib has been associated with concentration-dependent QT prolongation; ventricular arrhythmias and torsade de pointes TdP have been reported in postmarketing experience with lapatinib.
Lefamulin: Minor Coadministration of lefamulin and short-acting beta-agonists may increase the risk of QT prolongation. Lefamulin has a concentration dependent QTc prolongation effect. The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between lefamulin and other drugs that effect cardiac conduction is unknown.
Lenvatinib: Minor Beta-agonists should be used cautiously and with close monitoring with lenvatinib. Leuprolide: Minor Consider whether the benefits of androgen deprivation therapy i. Leuprolide; Norethindrone: Minor Consider whether the benefits of androgen deprivation therapy i. Levobetaxolol: Moderate Use of a betaselective cardioselective beta blocker is recommended whenever possible when this combination of drugs must be used together.
Levobunolol: Moderate Use of a betaselective cardioselective beta blocker is recommended whenever possible when this combination of drugs must be used together. Levofloxacin: Minor Levofloxacin should be used cautiously with short-acting beta-agonists as concurrent use may increase the risk for QT prolongation.
Levofloxacin has been associated with a risk of QT prolongation and TdP. Although extremely rare, TdP has been reported during postmarketing surveillance of levofloxacin. Levomethadyl is contraindicated in combination with other agents that may prolong the QT interval.
Agents with potential to prolong the QT interval include the beta agonists. Levothyroxine: Moderate Based on the cardiovascular stimulatory effects of beta-agonists and other sympathomimetics, concomitant use with thyroid hormones might enhance the effects on the cardiovascular system.
Concurrent use may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease. Levothyroxine; Liothyronine Porcine : Moderate Based on the cardiovascular stimulatory effects of beta-agonists and other sympathomimetics, concomitant use with thyroid hormones might enhance the effects on the cardiovascular system. Levothyroxine; Liothyronine Synthetic : Moderate Based on the cardiovascular stimulatory effects of beta-agonists and other sympathomimetics, concomitant use with thyroid hormones might enhance the effects on the cardiovascular system.
Linezolid: Moderate Linezolid may enhance the hypertensive effect of beta-agonists. Closely monitor for increased blood pressure during coadministration. Linezolid is an antibiotic that is also a weak, reversible nonselective inhibitor of monoamine oxidase MAO.
Therefore, linezolid has the potential for interaction with adrenergic agents, such as the beta-agonists. Liothyronine: Moderate Based on the cardiovascular stimulatory effects of beta-agonists and other sympathomimetics, concomitant use with thyroid hormones might enhance the effects on the cardiovascular system.
Lisdexamfetamine: Moderate Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Lithium: Minor Lithium should be used cautiously and with close monitoring with beta-agonists. Lithium has been associated with QT prolongation. Lofexidine: Minor Monitor ECG if lofexidine is coadministered with short-acting beta-agonists due to the potential for additive QT prolongation. Lofexidine prolongs the QT interval. In addition, there are postmarketing reports of torsade de pointes. Loop diuretics: Moderate Loop diuretics may potentiate hypokalemia and ECG changes seen with beta agonists.
Loperamide: Minor Coadministration of loperamide with beta-agonist may increase the risk for QT prolongation and torsade de pointes TdP. At high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, TdP and cardiac arrest.
Loperamide; Simethicone: Minor Coadministration of loperamide with beta-agonist may increase the risk for QT prolongation and torsade de pointes TdP. Lopinavir; Ritonavir: Major Avoid coadministration of lopinavir with short-acting beta-agonists due to the potential for additive QT prolongation.
If use together is necessary, obtain a baseline ECG to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Lopinavir is associated with QT prolongation. Loratadine; Pseudoephedrine: Moderate Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Macimorelin: Minor Concurrent use of macimorelin with short-acting beta-agonists may increase the risk of developing torsade de pointes-type ventricular tachycardia. Sufficient washout time of drugs that are known to prolong the QT interval prior to administration of macimorelin is recommended. Treatment with macimorelin has been associated with an increase in the corrected QT QTc interval. Maprotiline: Minor Maprotiline has been reported to prolong the QT interval, particularly in overdose or with higher-dose prescription therapy elevated serum concentrations.
Cases of long QT syndrome and torsade de pointes TdP have been described with maprotiline use, but rarely occur when the drug is used alone in normal prescribed doses and in the absence of other known risk factors for QT prolongation. Limited data are available regarding the safety of maprotiline in combination with other QT-prolonging drugs. Drugs with a possible risk for QT prolongation that should be used cautiously with maprotiline include the beta-agonists. Mefloquine: Minor While there is evidence that the use of halofantrine after mefloquine causes a significant lengthening of the QT interval, mefloquine alone has not been reported to cause QT prolongation.
However, due to the lack of clinical data, mefloquine should be used with caution in patients receiving drugs that prolong the QT interval. Drugs with a possible risk for QT prolongation that should be used cautiously with mefloquine include the beta-agonists. Beta agonists may cause adverse cardiovascular effects, usually with higher doses or when associated with hypokalemia.
Agents that prolong the QT interval could lead to torsade de pointes are contraindicated with mesoridazine and include the beta-agonists. Methacholine: Major Discontinue use of short-acting beta-agonists 6 hours before a methacholine challenge test. Beta-agonists inhibit the airway response to methacholine. Methadone: Minor The need to coadminister methadone with drugs known to prolong the QT interval should be done with extreme caution and a careful assessment of treatment risks versus benefits.
Methadone inhibits cardiac potassium channels and prolongs the QT interval. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. Drugs with a possible risk for QT prolongation that should be used cautiously and with close monitoring with methadone include the beta-agonists.
Methamphetamine: Moderate Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects. Methazolamide: Moderate Albuterol may cause additive hypokalemia when coadministered with carbonic anhydrase inhibitors.
Metoprolol: Moderate Use of a betaselective cardioselective beta blocker is recommended whenever possible when this combination of drugs must be used together. Metoprolol; Hydrochlorothiazide, HCTZ: Moderate Use of a betaselective cardioselective beta blocker is recommended whenever possible when this combination of drugs must be used together.
Midostaurin: Minor Concomitant use may result in additive effects on the QT interval. In clinical trials, QT prolongation was reported in patients who received midostaurin as single-agent therapy or in combination with cytarabine and daunorubicin. Mifepristone: Minor Mifepristone has been associated with dose-dependent prolongation of the QT interval. There is no experience with high exposure or concomitant use with other QT prolonging drugs.
To minimize the risk of QT prolongation, the lowest effective dose of mifepristone should always be used. Drugs with a possible risk for QT prolongation that should be used cautiously with mifepristone include the beta-agonists. Mirtazapine: Minor There may be an increased risk for QT prolongation and torsade de pointes TdP during concurrent use of mirtazapine and short-acting beta-agonists. Cases of QT prolongation, TdP, ventricular tachycardia, and sudden death have been reported during postmarketing use of mirtazapine, primarily following overdose or in patients with other risk factors for QT prolongation, including concomitant use of other medications associated with QT prolongation.
Monoamine oxidase inhibitors: Major Beta-agonists should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors MAOIs due to their sympathomimetic effects.
Moxifloxacin: Minor Prolongation of the QT interval has been reported with administration of moxifloxacin. Post-marketing surveillance has identified very rare cases of ventricular arrhythmias including torsade de pointes TdP , usually in patients with severe underlying proarrhythmic conditions. The likelihood of QT prolongation may increase with increasing concentrations of moxifloxacin, therefore the recommended dose or infusion rate should not be exceeded.
According to the manufacturer, moxifloxacin should be avoided in patients taking drugs that can result in prolongation of the QT interval.
Drugs with a possible risk for QT prolongation include beta-agonists. Nadolol: Moderate Use of a betaselective cardioselective beta blocker is recommended whenever possible when this combination of drugs must be used together.
Naproxen; Pseudoephedrine: Moderate Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Nebivolol: Moderate Use of a betaselective cardioselective beta blocker is recommended whenever possible when this combination of drugs must be used together. Nebivolol; Valsartan: Moderate Use of a betaselective cardioselective beta blocker is recommended whenever possible when this combination of drugs must be used together.
Nilotinib: Minor Coadministration of nilotinib with short-acting beta-agonists may increase the potential for additive QT prolongation. Sudden death and QT interval prolongation have occurred in patients who received nilotinib therapy. Norepinephrine: Major Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Although extremely rare, TdP has been reported during post-marketing surveillance of norfloxacin. These reports generally involved patients with concurrent medical conditions or concomitant medications that may have been contributory.
Norfloxacin should be used cautiously with other agents that may prolong the QT interval such as the beta-agonists. Nortriptyline: Minor Tricyclic antidepressants TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy elevated serum concentrations. Octreotide: Minor Use octreotide with caution in combination with short-acting beta-agonists.
This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists [such as albuterol]. Arrhythmias, sinus bradycardia, and conduction disturbances have occurred during octreotide therapy. Since bradycardia is a risk factor for development of torsade de pointes TdP , the potential occurrence of bradycardia during octreotide administration could theoretically increase the risk of TdP in patients receiving drugs that prolong the QT interval.
Ofloxacin: Minor Ofloxacin should be used cautiously with short-acting beta-agonists as concurrent use may increase the risk of QT prolongation. Quinolones have been associated with a risk of QT prolongation and TdP. Although extremely rare, TdP has been reported during postmarketing surveillance of ofloxacin. Olanzapine: Minor Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instances.
Therefore, caution is advised when administering olanzapine with drugs having an established causal association with QT prolongation. Drugs with a possible risk for QT prolongation include the beta-agonists. Olanzapine; Fluoxetine: Minor Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instances. Minor Use fluoxetine with caution in combination with short-acting beta-agonists. Olanzapine; Samidorphan: Minor Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instances.
Ondansetron: Minor Ondansetron has been associated with QT prolongation and post-marketing reports of torsade de pointes TdP. Osilodrostat is associated with dose-dependent QT prolongation. Osimertinib: Minor Use osimertinib and short-acting beta-agonists together with caution due to the risk of QT prolongation. The manufacturer of osimertinib recommends avoiding coadministration with other drugs that prolong the QT, if possible; if unavoidable, periodically monitor ECGs for QT prolongation and monitor electrolytes.
An interruption of osimertinib therapy with dose reduction or discontinuation of therapy may be necessary if QT prolongation occurs. Concentration-dependent QTc prolongation occurred during clinical trials of osimertinib. Oxaliplatin: Minor Monitor ECGs for QT prolongation and monitor electrolytes if coadministration is necessary; correct electrolyte abnormalities prior to administration of oxaliplatin. QT prolongation and ventricular arrhythmias including fatal torsade de pointes have been reported with oxaliplatin use in postmarketing experience.
This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists such as albuterol, levalbuterol, metaproterenol, pirbuterol, and terbutaline. Ozanimod: Minor Coadministration of ozanimod with short-acting beta-agonists may increase the potential for additive QT prolongation.
Ozanimod initiation may result in a transient decrease in heart rate and atrioventricular conduction delays. Ozanimod has not been studied in patients taking concurrent QT prolonging drugs; however, QT prolonging drugs have been associated with torsade de pointes in patients with bradycardia.
Paliperidone: Minor Paliperidone has been associated with QT prolongation; torsade de pointes TdP and ventricular fibrillation have been reported in the setting of overdose.
Drugs with a possible risk for QT prolongation that should be used cautiously with paliperidone include the beta-agonists.
Closely monitor patients with known risk factors for cardiac disease or arrhythmias during coadministration. Panobinostat: Minor QT prolongation has been reported with panobinostat therapy in patients with multiple myeloma in a clinical trial; use of panobinostat with other agents that prolong the QT interval is not recommended.
Obtain an electrocardiogram at baseline and periodically during treatment. Drugs with a possible risk for QT prolongation and torsade de pointes that should be used cautiously and with close monitoring with panobinostat include beta-agonists. Pasireotide: Minor Use caution when using pasireotide in combination with beta-agonists as concurrent use may increase the risk of QT prolongation.
QT prolongation has occurred with pasireotide at therapeutic and supra-therapeutic doses. Pazopanib: Minor Coadministration of pazopanib and other drugs that prolong the QT interval is not advised; pazopanib has been reported to prolong the QT interval. If pazopanib and the other drug must be continued, closely monitor the patient for QT interval prolongation. Drugs with a possible risk for QT prolongation that should be used cautiously with pazopanib include the beta-agonists.
Pemoline: Major Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects. Penbutolol: Moderate Use of a betaselective cardioselective beta blocker is recommended whenever possible when this combination of drugs must be used together. Pentamidine: Minor Pentamidine has been associated with QT prolongation.
Drugs with a possible risk for QT prolongation and torsade de pointes TdP should be used cautiously with pentamidine. Perphenazine: Minor Perphenazine, a phenothiazine, is associated with a possible risk for QT prolongation.
Drugs with a possible risk for QT prolongation and TdP that should be used cautiously with perphenazine include the beta-agonists. Perphenazine; Amitriptyline: Minor Perphenazine, a phenothiazine, is associated with a possible risk for QT prolongation.
Minor Tricyclic antidepressants TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy elevated serum concentrations. Phendimetrazine: Moderate Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Phenelzine: Major Beta-agonists should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors MAOIs due to their sympathomimetic effects. Phentermine: Moderate Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Phentermine; Topiramate: Moderate Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects. Phenylephrine: Moderate Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Pimavanserin: Minor Pimavanserin may cause QT prolongation and should be used with caution with beta-agonists. This risk may be more clinically significant with long-acting beta-agonists than with short-acting beta-agonists. Pimozide: Contraindicated Pimozide is associated with a well-established risk of QT prolongation and torsade de pointes TdP and should not be used with other drugs that might prolong the QT interval. Because of the potential for TdP, use of beta-agonists with pimozide is contraindicated.
Pindolol: Moderate Use of a betaselective cardioselective beta blocker is recommended whenever possible when this combination of drugs must be used together. Pitolisant: Minor Coadministration of pitolisant and short-acting beta-agonists may increase the risk of QT prolongation.
Pitolisant prolongs the QT interval. Ponesimod: Minor Concomitant use of ponesimod and short-acting beta-agonist may increase the risk of additive bradycardia, QT prolongation, and torsade de pointes TdP. Ponesimod initiation may result in a transient decrease in heart rate and atrioventricular conduction delays.
Ponesimod has not been studied in patients taking concurrent QT prolonging drugs; however, QT prolonging drugs have been associated with TdP in patients with bradycardia. Posaconazole: Minor Use posaconazole with caution in combination with short-acting beta-agonists as concurrent use may increase the risk of QT prolongation.
There is a problem with information submitted for this request. Sign up for free, and stay up-to-date on research advancements, health tips and current health topics, like COVID, plus expert advice on managing your health.
Error Email field is required. Error Include a valid email address. To provide you with the most relevant and helpful information and to understand which information is beneficial, we may combine your e-mail and website usage information with other information we have about you. If we combine this information with your PHI, we will treat all of that information as PHI, and will only use or disclose that information as set forth in our notice of privacy practices.
You may opt-out of e-mail communications at any time by clicking on the Unsubscribe link in the e-mail. Our Housecall e-newsletter will keep you up-to-date on the latest health information. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.
0コメント